CASE REPORT

Generalized granuloma annulare after pneumococcal vaccination ★,★

Miguel Fernando García-Gil ★ a,*, Marcial Álvarez-Salafranca ★ a, Alejandro Martínez García ★ b, Mariano Ara-Martín ★ a

a Department of Dermatology, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
b Department of Pathology, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain

Received 4 February 2020; accepted 17 May 2020

KEYWORDS
Case reports; Granuloma annulare; Vaccination

Abstract  Granuloma annulare may be caused by multiple triggers. Among these are vaccinations, which have been described as an infrequent cause of granuloma annulare. The authors report the first case of generalized granuloma annulare associated with pneumococcal vaccination in a 57-year-old woman, who presented cutaneous lesions 12 days after vaccination.

© 2020 Sociedade Brasileira de Dermatologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Introduction

The occurrence of granuloma annulare (GA) triggered by vaccination is rare, and the mechanism by which it is triggered can be explained by the trauma of inoculation or by the immune mechanism involved in vaccination.1-3

Case report

A 57-year-old woman with a medical history of hypothyroidism, hypercholesterolemia, and high blood pressure presented with a three-month history of asymptomatic skin lesions on the abdomen and lower extremities. Physical examination revealed multiple firm erythematous-violaceous papules clustered in an annular pattern and distributed along the abdomen and lower extremities (Fig. 1). A 13-valent pneumococcal conjugate vaccine (PCV-13) was identified as a possible trigger, since it had been administered 12 days prior to the onset of the skin lesions. A skin biopsy of the abdominal lesion was performed. Histopathological examination revealed foci of chronic interstitial inflammation and collagen necrobiosis with an associated lymphohistiocytic infiltrate (Fig. 2).

How to cite this article: García-Gil MF, Álvarez-Salafranca M, Martínez García A, Ara-Martín M. Generalized granuloma annulare after pneumococcal vaccination. An Bras Dermatol. 2021;96 https://doi.org/10.1016/j.abd.2020.05.009

* Corresponding author.
E-mail: miguelgarcigil@outlook.com (M.F. García-Gil).

https://doi.org/10.1016/j.abd.2020.05.009
0365-0596/© 2020 Sociedade Brasileira de Dermatologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
The patient was diagnosed with generalized GA following pneumococcal vaccination based on the clinical appearance of the lesions, histopathological findings, and temporal relationship between the vaccinations and skin lesions. Treatment using mometasone furoate cream was initiated; however, no improvement was apparent after one month. The lesions eventually resolved spontaneously within two months of their initial appearance.

**Discussion**

Only 13 cases of GA following vaccination have been reported in the literature. The bacillus Calmette-Guérin (BCG) vaccine has been most frequently reported to be causative vaccine (eight cases), followed by the hepatitis B vaccine (HBV; two cases) and the influenza, tetanus and diphtheria–tetanus toxoid vaccines (one case each). An association between the pneumococcal vaccine and GA has not been previously described (Table 1).

The occurrence of GA triggered by vaccination has been reported to be higher in females (61.54%, eight cases) than in males (38.46%, five cases). The generalized form (76.92%, ten cases) is the most frequently described clinical form of GA triggered by vaccination, with the localized form accounting only for 23.08% of the cases (3 cases). The ages of the affected patients ranged from 3 months to 76 years (average, 16.74 years; median, 3 years). The latency between vaccination and the appearance of GA has been reported to range from 5 days to 2 months (average, 1.22 months; median, 1 month).

GA completely healed in most reported cases (10 cases). However, partial improvement was observed in one case, while no improvement was observed in another case. Overall, the mean resolution time was 4.37 months in the completely healed cases (median, 3 months). GA recurred following re-vaccination with the HBV and tetanus vaccines in two cases, with a latency of 3 weeks in both the cases. The latency to recurrence was thus shorter in the cases with re-vaccinations.

The mechanism by which GA is triggered is unknown. Immunological activation after vaccination would explain the presence of activated T-cells in the lymphocytic infiltrate of GA, suggesting the existence of a mediated immune response.

GA triggered by vaccination could have an immunological pathogenesis, as generalized GA has been observed in most cases. The traumatic inoculation hypothesis is less convincing, because GA exclusively located at the vaccination site has been observed in few cases.

The short latency between vaccination and the appearance of GA, which has been reported to be around 1 month in most cases, supports the causal relationship between vac-
Table 1  Cases of granuloma annulare triggered by vaccination.

<table>
<thead>
<tr>
<th>Authors</th>
<th>Year</th>
<th>Vaccine</th>
<th>Dose</th>
<th>Sex</th>
<th>Age</th>
<th>Localized/generalized latency time</th>
<th>Treatment</th>
<th>Resolution</th>
<th>Revaccination recurrence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Houcke-Bruge C et al.</td>
<td>2001</td>
<td>BCG</td>
<td>1 dose</td>
<td>Male</td>
<td>3 years</td>
<td>Generalized</td>
<td>No</td>
<td>Complete, 3 months</td>
<td>Complete, 3 months</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1 dose</td>
<td>Female</td>
<td>2 years</td>
<td>Location remote from vaccination site</td>
<td>No</td>
<td>Complete, 3 months</td>
<td>Complete, 3 months</td>
</tr>
<tr>
<td>Kakurai M et al.</td>
<td>2001</td>
<td>BCG</td>
<td>1 dose</td>
<td>Male</td>
<td>12 years</td>
<td>Generalized</td>
<td>Moisturizer, 3 months</td>
<td>Complete, 7 months</td>
<td>Complete, 3 months</td>
</tr>
<tr>
<td>Nagase K et al.</td>
<td>2011</td>
<td>BCG</td>
<td>1 dose</td>
<td>Male</td>
<td>5 months</td>
<td>Generalized</td>
<td>Topical corticosteroids, 1 month</td>
<td>Complete, 3 months</td>
<td>Complete, 1 month</td>
</tr>
<tr>
<td>Lee SW et al.</td>
<td>2011</td>
<td>BCG</td>
<td>1 dose</td>
<td>Female</td>
<td>3 months</td>
<td>Generalized</td>
<td>Topical corticosteroids 1 month</td>
<td>Complete, 1 month</td>
<td>Complete, 3 months</td>
</tr>
<tr>
<td>Nomiyama T et al.</td>
<td>2013</td>
<td>BCG</td>
<td>1 dose</td>
<td>Female</td>
<td>6 months</td>
<td>Generalized</td>
<td>Topical corticosteroids 1 month</td>
<td>Complete, 1 month</td>
<td>Complete, 3 months</td>
</tr>
<tr>
<td>Yoon NY et al.</td>
<td>2014</td>
<td>BCG</td>
<td>1 dose</td>
<td>Male</td>
<td>3 months</td>
<td>Generalized</td>
<td>Ceftriaxone for 8 days and prophylactic hydroxyzine for 3 weeks</td>
<td>Complete, 3 weeks</td>
<td>Complete, 3 weeks</td>
</tr>
<tr>
<td>Yang SY et al.</td>
<td>2018</td>
<td>BCG</td>
<td>1 dose</td>
<td>Male</td>
<td>3 months</td>
<td>Localized</td>
<td>No</td>
<td>Complete, 18 months</td>
<td>Complete, 18 months</td>
</tr>
</tbody>
</table>
Table 1 (Continued)

<table>
<thead>
<tr>
<th>Authors</th>
<th>Year</th>
<th>Vaccine</th>
<th>Dose</th>
<th>Sex</th>
<th>Age</th>
<th>Latency time</th>
<th>Treatment</th>
<th>Resolution</th>
<th>Revaccination recurrence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wolf F et al.</td>
<td>1998</td>
<td>Hepatitis B virus</td>
<td>4 doses (0 months, 1 month, 2 months, 12 months)</td>
<td>Female</td>
<td>51</td>
<td>1 month after the last vaccine</td>
<td>Dapsone 50 mg/day 4 months</td>
<td>Complete, 4 months (subsequent recurrence)</td>
<td>Revaccination at 5 years (latency time of 3 weeks)</td>
</tr>
<tr>
<td>Criado PR et al.</td>
<td>2004</td>
<td>Hepatitis B virus</td>
<td>2 doses (0 months, 1 month)</td>
<td>Female</td>
<td>58</td>
<td>2 months after the last vaccine</td>
<td>Topical corticosteroids</td>
<td>Partial improvement, 3 months</td>
<td></td>
</tr>
<tr>
<td>Baykal C et al.</td>
<td>2002</td>
<td>Tetanus</td>
<td>1 dose</td>
<td>Female</td>
<td>6</td>
<td>2 months after the last vaccine</td>
<td>Triamcinolone ace-tonide 10 mg/mL every 4 weeks, intrallesional (3 sessions)</td>
<td>Complete, 3 months (subsequent recurrence)</td>
<td>Revaccination (latency time of 3 days)</td>
</tr>
<tr>
<td>Baskan EB et al.</td>
<td>2005</td>
<td>Diphtheria and tetanus toxoid</td>
<td>1 dose</td>
<td>Female</td>
<td>8</td>
<td>1 week</td>
<td>Topical corticosteroids</td>
<td>No improvement</td>
<td></td>
</tr>
<tr>
<td>Suzuki T et al.</td>
<td>2014</td>
<td>Influenza</td>
<td>1 dose</td>
<td>Female</td>
<td>76</td>
<td>1 month</td>
<td>No</td>
<td>No follow-up</td>
<td></td>
</tr>
</tbody>
</table>

PCV-13, 13-valent pneumococcal conjugate vaccine; BCG vaccine, Bacillus Calmette-Guérin vaccine.
Generalized granuloma annulare after pneumococcal vaccination

Recurrence following re-vaccinations and the concomitant shorter latency further support this argument. After the cessation of immunological stimulation, GA healed completely in most cases, including in the present case.\textsuperscript{1,2,4-7,10} Notably, most cases occurred in young patients, probably because the frequency of vaccination is higher at a younger age. However, cases have also been observed in older patients.

In conclusion, the majority of reported cases of GA are of the generalized form, which indicates a possible immunological pathogenesis. Complete resolution was observed within a few months after vaccination in most cases, and recurrence occurred on re-vaccination.

Financial support

None declared.

Authors’ contributions

Miguel Fernando García-Gil: Statistical analysis; approval of the final version of the manuscript; design and planning of the study; drafting and editing of the manuscript; collection, analysis, and interpretation of data; effective participation in research orientation; intellectual participation in the propaedeutic and/or therapeutic conduct of the studied cases; critical review of the literature; critical review of the manuscript.

Marcial Álvarez-Salafranca: Statistical analysis; approval of the final version of the manuscript; design and planning of the study; drafting and editing of the manuscript; collection, analysis, and interpretation of data; effective participation in research orientation; intellectual participation in the propaedeutic and/or therapeutic conduct of the studied cases; critical review of the manuscript.

Alejandro Martínez García: Statistical analysis; approval of the final version of the manuscript; design and planning of the study; drafting and editing of the manuscript; collection, analysis, and interpretation of data; effective participation in research orientation; intellectual participation in the propaedeutic and/or therapeutic conduct of the studied cases; critical review of the literature; critical review of the manuscript.

Mariano Ara-Martín: Statistical analysis; approval of the final version of the manuscript; design and planning of the study; drafting and editing of the manuscript; collection, analysis, and interpretation of data; effective participation in research orientation; intellectual participation in the propaedeutic and/or therapeutic conduct of the studied cases; critical review of the manuscript.

Conflicts of interest

None declared.

References